Prior to joining Adenium, Dr. Fang was Director of Clinical Sciences at Trius Therapeutics where he was the clinical lead on pivotal phase 3 skin infection studies, as well as phase 1 and 2 trials, and contributed to the NDA leading to the approval of Sivextro (tedizolid) by the FDA (Jun 2014). Previously, Dr. Fang was Associate Director of Clinical Sciences at Cerexa, where he was the clinical lead on phase 1 and 2 studies, and contributed to the NDA leading to the approval of Teflaro (ceftaroline) by the FDA (Oct 2010). Earlier, Dr. Fang was Editor-in-Chief at Epocrates, developing content and products for software used by physicians and other healthcare professionals. Dr. Fang earned a BA from Stanford University, and an MD from the University of California at Los Angeles, where he also completed a residency in internal medicine.